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The increase in demand for renal replacement therapy makes
it important to investigate the prognosis of the earlier stages
of chronic kidney disease (CKD). We examined the change in
glomerular filtration rate (GFR), and patient and renal survival
in CKD stage 3 in the municipality of Tromsø, a well-defined
European community with a population of 58 000. All
patients with estimated GFR between 30 and 59 ml/min/
1.73 m2 for more than 3 months during a 10-year study
period were identified from a complete database of all
248 560 measurements of serum creatinine made in the
community in the study period. Change in GFR was estimated
for each patient using a multilevel model. A complete
follow-up with respect to patient and renal survival
was obtained from hospital databases. A total of 3047
patients was included. The median number of measurements
of creatinine for each patient was 9, and the median
observation time was 44 months. Mean estimated
change in GFR was 1.03 ml/min/1.73 m2/year. Seventy-three
percent of the patients experienced a decline in GFR.
The 10-year cumulative incidence of renal failure was 0.04
(95% CI 0.03–0.06) and mortality 0.51 (95% CI 0.48–0.55).
Female gender was associated with slower decline
in GFR and better patient and renal survival. In this
population-based study, the decline in GFR in CKD was
slower than in previously studied selected patient groups. A
high mortality pre-empted the development of renal failure
in many patients. The prognosis of CKD depended strongly
on gender.
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The need for renal replacement therapy (RRT), that is,
dialysis or kidney transplantation, is increasing rapidly. In
most countries, demand will exceed capacity for providing
this kind of costly care in a few years.1 One solution to the
problem would be to prevent the progression of chronic
kidney disease (CKD) to renal failure. Researchers are now
focusing on the milder forms of CKD and therapy that may
retard or even reverse its progression.
As a prerequisite for this research, the National Kidney
Foundation Kidney Disease Outcomes Quality Initiative to
establish a consensus definition of the term ‘chronic kidney
disease’ has met broad approval among nephrologists. The
finding of a reduced glomerular filtration rate (GFR) and/or
structural damage to the kidney of more than three months
duration can now be used for categorizing CKD into five
stages from chronic kidney damage with normal GFR (stage
1) to kidney failure with GFR less than 15 ml/min/1.73 m2
body surface area (stage 5).2 This classification is intended as
a starting point both for research and for establishing clinical
guidelines.
To serve these purposes, it would be useful if each stage
was, to some extent, homogenous in clinical manifestations,
especially with regard to progression to renal failure. Previous
studies of the prognosis of CKD do not provide a clear
answer to this issue. The largest epidemiological studies of
CKD were not longitudinal,3,4 the longitudinal ones did not
provide estimates of change in GFR,5–9 and some were based
on selected populations.6,7,9 Also, some recent studies did not
verify that a reduced GFR persisted for 3 months or more, as
required by the definition, thereby risking bias from
including patients with reversible acute renal failure.4,9
The present longitudinal observation study was under-
taken to investigate the long-term prognosis and change in
GFR of a cohort of patients with CKD stage 3, which is the
least advanced stage defined from GFR alone.2 The cohort
was identified from all serum creatinine measurements in a
population within a well-defined geographic area being
served by one provider of nephrological services in a health
care system with universal coverage. There was complete
follow-up of initiation of RRT and deaths. The aim of
the study was to examine the effects of gender and age on the
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rate of change in GFR, initiation of RRT, and all-cause
mortality.
RESULTS
Of the 38 241 patients with measurements of creatinine, 6863
had one or more GFR estimate in the interval 30–59 ml/min/
1.73 m2. Of these, 88 had subsequent estimates lower than 30
and 2175 greater than 59 ml/min/1.73 m2, which excluded
them according to the 3-month requirement of the defini-
tion. A total of 1526 patients had no second measurement
more than 3 months after the first. Thus, 3074 patients, who
were all 20 years or older, satisfied the definition of CKD
stage 3. After excluding 27 patients on RRT, 3047 patients
were included in the study.
Of these, 30% were men and 70% women (Table 1).
Median observation time was 44 months (mean 50 months)
during which each patient was subjected to a median of nine
analyses of creatinine (mean 14 analyses).
Survival analysis
In the study period, 959 (31%) of the patients died and 62
(2%) developed renal failure (CKD stage 5 or initiation of
RRT) (Table 1). Of the 58 patients with CKD stage 5, 24
subsequently received RRT (19 dialysis, five kidney trans-
plant), and of the rest 30 were dead and four alive at the end
of the study period.
Table 2 shows the cumulative 5- and 10-year incidence of
the two end points. For all patients, the 10-year cumulative
incidence of renal failure was 0.04, and that of death was 0.51.
The cumulative incidences of both end points were higher for
men, but increasing age led to higher mortality but lower
cumulative incidence of renal failure. Cox proportional-
hazards regression analyses found age, gender, and baseline
GFR significant regressors for both endpoints and confirmed
the opposite effects of age on renal failure and mortality
(Table 3). Interactions between these three regressors were
tested in both analyses, but none were found significant.
Non-linear effects of age and GFR were tested by adding
quadratic terms for these variables to both models, but none
was statistically significant.
Table 1 | Baseline characteristics of cohort of patients with CKD stage 3
Men Women Total
No. (%) 928 (100) 2119 (100) 3047 (100)
Median age (IQR)a 75.0 (67.7–80.4) 75.0 (66.3–81.5) 75.0 (67.0–81.2)
Median GFR at baseline (IQR) (ml/min/1.73 m2) 54.7 (49.9–57.7) 55.3 (51.1–58.0) 55.1 (50.8–57.9)
Median observation time (IQR) (months) 39 (20–67) 47 (28–71) 44 (26–69)
Median number of creatinine analyses (IQR) 12 (6–22) 8 (4–15) 9 (4–17)
Patients with fewer than 3 analyses (%) 7 11 10
End points,no. (%)
Renal failure
Chronic kidney disease stage 5 33 (4) 25 (1) 58 (2)
Renal replacement therapy 2 (0.2) 2 (0.1) 4 (0.1)
Death 383 (41) 576 (27) 959 (31)
Censored 510 (55) 1516 (72) 2026 (66)
aIQR denotes interquartile range.
Table 2 | Cumulative 5- and 10-year incidence of the
competing risks renal failure and death in patients with CKD
stage 3 (n=3047)
Age Men Women Total
o69 years
No. (%) 279 (28) 704 (72) 983 (100)
Cumulative incidence (95% CI)a
Renal failureb
5-year 0.05 (0.03–0.09) 0.02 (0.01–0.03) 0.03 (0.02–0.04)
10-year 0.12 (0.08–0.20) 0.04 (0.02–0.08) 0.07 (0.05–0.11)
Death
5-year 0.20 (0.16–0.27) 0.08 (0.06–0.11) 0.12 (0.10–0.15)
10-year 0.26 (0.20–0.35) 0.13 (0.09–0.17) 0.17 (0.14–0.21)
70–79 years
No. (%) 404 (35) 759 (65) 1163 (100)
Cumulative incidence (95% CI)
Renal failure
5-year 0.02 (0.01–0.04) 0.01 (0.01–0.02) 0.01 (0.01–0.02)
10-year 0.06 (0.03–0.11) 0.03 (0.01–0.07) 0.04 (0.02–0.07)
Death
5-year 0.41 (0.35–0.46) 0.21 (0.18–0.25) 0.28 (0.25–0.31)
10-year 0.65 (0.58–0.73) 0.40 (0.35–0.46) 0.49 (0.45–0.54)
479 years
No. (%) 245 (27) 656 (73) 901 (100)
Cumulative incidence (95% CI)
Renal failure
5-year 0.02 (0.01–0.05) 0.01 (0.00–0.02) 0.01 (0.00–0.02)
10-year 0.05 (0.03–0.11) 0.01 (0.00–0.03) 0.03 (0.01–0.05)
Death
5-year 0.64 (0.57–0.71) 0.53 (0.49–0.57) 0.56 (0.52–0.60)
10-year 0.88 (0.81–0.95) 0.83 (0.77–0.89) 0.84 (0.80–0.89)
Total
No. (%) 928 (30) 2119 (70) 3047 (100)
Cumulative incidence (95% CI)
Renal failure
5-year 0.03 (0.02–0.04) 0.01 (0.01–0.02) 0.02 (0.01–0.02)
10-year 0.08 (0.05–0.11) 0.03 (0.02–0.04) 0.04 (0.03–0.06)
Death
5-year 0.41 (0.38–0.45) 0.28 (0.26–0.30) 0.32 (0.30–0.34)
10-year 0.61 (0.56–0.67) 0.47 (0.43–0.50) 0.51 (0.48–0.55)
aCI denotes confidence interval.
bRenal failure was defined as irreversible CKD stage 5 or initiation of RRT.
376 Kidney International (2006) 69, 375–382
o r i g i n a l a r t i c l e BO Eriksen and OC Ingebretsen: Progression of chronic kidney disease
The possibility of bias because renal failure was not
detected in patients who died was examined by estimating
expected GFR at the time of death from a linear model
for disease progression for each patient. Patients falling
below a GFR of 15 ml/min/1.73 m2 before death were
then considered to have experienced CKD stage 5 and
the Cox proportional-hazards regression analyses repeated.
The results were not materially different from those presented
above.
Standardized incidence rate ratios for death and renal
failure relative to the Tromsø population were estimated
(Table 4). For both death and renal failure, the ratios
demonstrated increased incidence rates for CKD stage 3,
especially for the youngest age group. There were higher renal
failure ratios for men than for women, but the differences
were not statistically significant.
Change in GFR
In the multi-level model, gender and age were significant
regressors of both baseline GFR and change in GFR (Table 5).
Both dependent variables decreased with increasing age and
for male gender. Interactions between age and gender in both
equations (2) and (3) were tested. While this demonstrated
that the gender difference in baseline GFR was the highest for
the younger age groups (P¼ 0.002), there was no interaction
between age and gender for change in GFR (P¼ 0.53). When
including a quadratic term for age in equation (3), a weak
effect on change in GFR was also significant (P¼ 0.02), but
was found non-significant when the nine patients in the age
group 20–29 years were excluded from the analysis.
In Table 6, estimates of change in GFR under the model
conditional on the observed GFRs are tabulated according to
age and gender. The mean overall change in GFR was
Table 3 | Cox proportional-hazards regression analyses of the effects of age, gender, and GFR at baseline on the competing
risks renal failure and death (n=3047)
Renal failure Death
Baseline variables Hazard ratio 95% confidence interval P-value Hazard ratio 95% confidence interval P-value
Female gender 0.35 0.21–0.59 o0.0001 0.55 0.48–0.62 o0.0001
Age (10 year increment) 0.75 0.63–0.89 0.0009 2.28 2.11–2.46 o0.0001
GFR at baseline (10 ml/min/1.73 m2 decrement) 2.50 1.89–3.31 o0.0001 1.25 1.14–1.37 o0.0001
Table 4 | Standardized incidence rate ratios for death and renal failure for patients with CKD stage 3 (n=3047) relative to the
general population of Tromsø
Men Women Total
Age (years) Ratio 95% confidence interval Ratio 95% confidence interval Ratio 95% confidence interval
o69
Renal failurea 48.0 (22.7–101.5) 27.0 (11.9–61.2) 36.6 (21.2–63.2)
Death 3.6 (2.6–5.0) 2.7 (2.0–3.7) 3.1 (2.5–3.9)
70–79
Renal failure 4.2 (1.8–9.6) 3.8 (1.8–8.3) 3.1 4.0 (2.3–7.0)
Death 2.4 (2.0–2.9) 1.8 (1.5–2.1) 2.0 (1.8–2.3)
479
Renal failure 4.6 (2.4–8.9) 2.6 (1.1–6.2) 3.7 (2.2–6.2)
Death 2.3 (2.0–2.6) 2.1 (1.9–2.3) 2.2 (2.0–2.3)
Total
Renal failure 6.5 (4.3–9.9) 4.3 (2.7–6.9) 5.3 (3.9–7.3)
Death 2.4 (2.2–2.7) 2.1 (1.9–2.3) 2.2 (2.1–2.4)
aRenal failure was defined as irreversible CKD stage 5 or initiation of RRT.
Table 5 | Multilevel multivariate linear regression analysis of the effects of age and gender on GFR in CKD stage 3 (n=3047)
Baseline GFR
(ml/min/1.73 m2)
Change in GFR per year
(ml/min/1.73 m2/yeara)
Baseline variables
Regression
coefficient
(ml/min/1.73 m2)
95% confidence
interval P-value
Regression
coefficient
(ml/min/1.73 m2/year)
95% confidence
interval P-value
Estimate for 60-year-old male 53.70 53.13 to 54.27 o0.0001 0.88 1.18 to 0.59 o0.0001
Female gender 1.21 0.62 to 1.80 o0.0001 0.50 0.20 to 0.81 0.001
Age, 10 year increment 0.72 0.95 to 0.49 o0.0001 0.38 0.51 to 0.26 o0.0001
aThis translates to a mean change in GFR per year at ages 30, 40, 50, 60, 70, 80 years of 0.26, 0.12, 0.50, 0.88, 1.26, 1.64 ml/min/1.73 m2/year for men, and 0.76, 0.38,
0.00, 0.38, 0.76, 1.14 ml/min/1.73 m2/year for women. A positive change signifies an increase in GFR with time, a negative change a decreasing GFR.
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1.03 ml/min/1.73 m2/year. Seventy-three percent of the
patients had a change in GFR less than 0 and 6% less than
5 ml/min/1.73 m2/year (Figure 1).
DISCUSSION
CKD has traditionally been regarded as unremittingly
progressive when GFR falls below a hypothesized point of
no return. However, in the Modification of Diet in Renal
Disease study, as many as 19% of patients with GFR between
25 and 55 ml/min/1.73 m2 experienced improvement or
stabilization of their renal function during the 2-year study
period.10 The results of the present study show that an even
higher percentage of CKD patients in clinical practice may
have favorable renal prognoses, as 27% did not experience a
decline in GFR during a mean observation time of more than
four years (Table 6).
The mean decline in GFR of about 1 ml/min/1.73 m2/year
was also markedly lower than in the Modification of Diet in
Renal Disease study (4 ml/min/1.73 m2/year).10 Still, a
significant percentage of CKD stage 3 patients (6%)
experienced a rapid progression towards renal failure (change
in GFR o5 ml/min/1.73 m2/year), although few actually
reached the end point. However, mortality at 10 years was
more than 50%. The same pattern was found by Keith et al.7
in their study of members of Health Maintenance Organiza-
tion (HMO) in Oregon. Although a formal survival analysis
was not performed, 24% of patients with CKD stage 3 died
during a 51-month observation period, whereas only 1.3%
started on RRT.
To investigate the possibility of bias due to undetected
renal failure at death, all analyses in the present study were
repeated with GFR estimated at the time of death, with
similar results. Thus, patients died from other causes before
they developed renal failure. This relation between the
competing risks of death and renal failure was particularly
pronounced for older patients and was also found by Collins
et al.11 in their study of Medicare patients with CKD in the
US. Whereas increasing age was associated with a faster GFR
decline, older patients had a lower cumulative incidence of
renal failure. The high prevalence of ESRD at high ages
observed in renal registries must therefore be explained by
the high prevalence of CKD in these age groups.4
Table 6 | Estimated mean change in GFR in patients with CKD stage 3 according to gender and age (n=3047)
Age Men Women Total
o69 years
No. (%) 279 (28) 704 (72) 983 (100)
Mean DGFR (ml/min/1.73 m2/year)a 0.94 0.33 0.50
Patients with DGFR o0 ml/min/1.73 m2/year (%) 69 58 61
Patients with DGFR o5 ml/min/1.73 m2/year (%) 9 3 5
70–79 years
No. (%) 404 (35) 759 (65) 1163 (100)
Mean DGFR (ml/min/1.73 m2/year) 1.29 0.91 1.04
Patients with DGFR o0 ml/min/1.73 m2/year (%) 76 75 75
Patients with DGFR o5 ml/min/1.73 m2/year (%) 7 4 5
479 years
No. (%) 245 (27) 656 (73) 901 (100)
Mean DGFR (ml/min/1.73 m2/year) 2.07 1.43 1.60
Patients with DGFR o0 ml/min/1.73 m2/year (%) 87 82 83
Patients with DGFR o5 ml/min/1.73 m2/year (%) 9 6 7
Total
No. (%) 928 (30) 2119 (70) 3047 (100)
Mean DGFR (ml/min/1.73 m2/year) 1.39 0.88 1.03
Patients with DGFR o0 ml/min/1.73 m2/year (%) 77 71 73
Patients with DGFR o5 ml/min/1.73 m2/year (%) 8 4 6
aDGFR denotes change in GFR. Estimates of the underlying change in GFR for each patient under the statistical model conditional on the observed GFRs was used (see text).
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Figure 1 | Box-plot of distribution of estimated change in GFR in
patients with CKD stage 3 according to age group (n¼ 3047).
Boxes indicate interquartile range with middle line representing
median. Whiskers indicate largest observation that is less than or
equal to the 75th percentile plus 1.5 times interquartile range and
smallest observation that is greater than or equal to the 25th
percentile minus 1.5 times interquartile range. Values that are less
than three interquartile ranges from the 25th and 75th percentiles are
shown as black dots, and those outside three interquartile ranges as
gray dots.
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CKD stage 3 was associated with increased incidence rates
of both renal failure and death compared to the general
population, particularly for those younger than 70 years
(Table 4). Other investigations have found CKD an
independent risk factor for both all-cause and cardiovascular
mortalities.9,12 Accordingly, for most CKD patients the risk of
cardiovascular disease far outweighs the risk of renal failure.
This has important consequences for the clinical manage-
ment of this patient group. Intervention against cardio-
vascular risk factors, as for example, hypercholesterolemia,
may be more important than preparing patients for RRT. A
recent meta-analysis of randomized controlled trials found
that statins were effective in reducing cardiovascular events in
patients with CKD stage 3.13
In the present study, the prognosis of CKD depended on
gender. Male gender had a negative effect on both decline of
GFR and hazard of renal failure. The finding of twice as many
women as men with CKD stage 3 raises the possibility that
this could have been caused by selection bias from a failure to
detect men with a good prognosis. Table 7 shows that there
were fewer measurements of creatinine per person year for
men than for women in the younger age groups. However,
the proportion of men with CKD stage 3 among those who
were tested was low as well, whereas the opposite would be
typical if men were underdiagnosed. Also, the gender effects
were uniform across age for both mortality, renal failure and
rate of change in GFR, even though the gender differences in
number of measurements varied widely across age. Finally,
the prevalence of CKD stage 3 for men has been found lower
than for women in other studies, as for example, in the third
National Health and Nutrition Examination Survey, where
the prevalence for men was 3.4% and for women 5.1%.4 It is
therefore unlikely that selection bias was the only explanation
for the gender differences found in this study.
The effect of gender on the progression of CKD has been a
matter of debate, where most of the evidence seems to point
towards a negative effect of male gender.14,15 In a recent study
from Washington county, Haroun et al.6 found a relative risk
of developing a need for RRT of 1.7 for men, when adjusting
for blood pressure, diabetes, and smoking. In contrast, Jafar
et al.16 found that the gender difference was reversed when
correcting for baseline covariates in a meta-analysis of
randomized controlled trials, indicating that the adjusted
effect of male gender might be protective. The results of the
present study indicate that preventive measures may be
particularly important in men, and even more so if their
adverse prognosis is caused by modifiable risk factors.
The different prognoses of CKD stage 3 in identifiable
subgroups make it difficult to establish guidelines with a
uniform approach to these patients. A patient with stable
GFR may need more attention to an increased risk of
cardiovascular disease, whereas patients with progressive
disease must also be prepared for RRT. Old patients may
benefit less from intensive diagnostic and therapeutic efforts
than younger patients. The different risk profiles of men and
women may require different approaches. The present
National Kidney Foundation Kidney Disease Outcomes
Quality Initiative guidelines do not incorporate different
approaches to subgroups of the CKD population, presumably
because the evidence base has been lacking. More research is
needed. The most important issue is to establish risk factors
for predicting which patients will progress and which have a
stable disease. Such risk factors should be included in the
staging of CKD. The most obvious candidate is proteinuria,
which is known to be associated with progressive disease.2
Although included in the definition of stages 1 and 2,
definitions of the more advanced stages have been made
without taking proteinuria into account. This needs to be
reconsidered.
The most important limitation of the present study was
that measurements of creatinine were made for clinical
purposes. This may have selected patients with a more
serious disease and biased our estimates towards a faster rate
of decline in GFR and higher incidences of the endpoints.
However, this strengthens our conclusion that CKD is less
progressive and has a lower risk of RRT than previously
Table 7 | Number of included patients with CKD stage 3 and creatinine measurements per person year in the Tromsø
population
Number of
patients with
CKD stage 3
CKD stage 3
patients per 1000
measurements
Total number
of creatinine
measurements
Measurements
per person
year
Total number
of person years
in study period
Age group (years) Men Women Men Women Men Women Men Women Men Women
0–9 3 227 2 631 0.07 0.06 46 543 42 515
10–19 3 525 4 215 0.10 0.13 34 769 32 985
20–29 9 6 1.2 0.5 7 365 11 537 0.16 0.24 46 031 48 594
30–39 5 21 0.5 1.4 10 526 15 161 0.20 0.29 52 437 51 883
40–49 31 81 2.1 4.7 14 503 17 157 0.33 0.40 44 224 42 412
50–59 57 216 3.0 10.5 18 794 20 529 0.59 0.69 32 056 29 887
60–69 177 380 8.8 21.2 20 173 17 965 1.16 1.00 17 439 18 025
70–79 404 759 16.2 30.4 24 865 25 000 2.12 1.61 11 746 15 560
80–89 204 571 19.0 34.0 10 762 16 788 2.82 2.04 3 810 8 224
490 41 85 29.9 34.4 1 369 2 468 3.15 1.91 434 1 289
Total 928 2119 8.1 15.9 115 109 133 451 0.40 0.46 289 489 291 374
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estimated. In contrast, a possibility, that a significant number
of patients with manifest CKD should not have been
represented in the creatinine database seems unlikely. In
fact, virtually all patients who actually developed a need for
RRT in the study period were included in the study
population. In Tromsø, routine creatinine analyses were
made as a part of most consultations in both primary care
and outpatient clinics, and the resulting number of
measurements relative to the population size was very high
(Table 7). The ideal study design would have been a random
sample survey with prescheduled repeated measurements for
the same follow-up period. However, even the estimates from
a survey would not have been entirely unbiased, as elderly
and diseased patients would have been less likely to attend.
Another problem in using routine analyses of creatinine
for estimating changes in GFR over a long time period is to
ensure stability of the assay. Although rigorous quality
control routines are a safeguard against larger fluctuations,
long-term drift cannot be completely excluded. To explore
this issue, we repeated the multilevel regression analysis with
covariates for measurement year, which did not materially
alter the results. Variations in the calibration of serum
creatinine assays relative to the laboratory used in the
Modification of Diet in Renal Disease study have also been
observed with corresponding variations in estimated GFR
from the abbreviated Modification of Diet in Renal Disease
formula.17 However, this problem would affect absolute
values most and is of less importance for change in GFR,
which was the main focus of the present study.
The clinical manifestations of CKD are known to depend
on ethnic and socioeconomic factors. The predominantly
Caucasian population of Tromsø includes a small minority
with Sa´mi background, but there are no studies of kidney
disease in this group, and the creatinine database did not
include information on ethnicity. The socioeconomic status
of Norway is somewhat above the average for developed
countries.18 This may have contributed to lower the
incidence of CKD, whereas little is known about how it
might have affected prognosis.5,19 Altogether, Tromsø is
probably fairly representative of populations in the developed
world.
We conclude that the tendency of CKD stage 3 to progress
to renal failure is less than estimated from studies of selected
patient groups, and that high mortality forestalls the
development of renal failure in many patients. Both high
age and male gender are independent predictors of poor
prognosis. The present staging system for CKD focuses on
level of GFR rather than on rate of progression. It should be
improved to accommodate the need for different approaches
to subgroups of patients by placing more emphasis on
prognostic factors.
MATERIALS AND METHODS
Subjects and data
In the 10-year study period from 1 January 1994 to 31 December
2003, the annual mean population of Tromsø, a municipality in
Northern Norway, was 58 086. The University Hospital of North
Norway, which is located in the municipality, is its sole provider of
nephrology and laboratory services.
In the hospital’s database of serum creatinine analyses, persons
are uniquely identified by date of birth and person number. The
subjects of the study are the 38 241 persons identified by postcode
analysis as living in the municipality of Tromsø. In total, these
subjects had had 248 560 measurements of creatinine performed by
the hospital’s laboratory as a part of routine clinical activities in the
study period. This included all health care in the municipality, both
primary care and hospital in- and outpatients. Table 7 shows the
number of creatinine measurements and person years in the total
population. Population data were obtained from the website of
Statistics Norway.20
As the aerial distance to the next hospital and laboratory is
150 km and by road 300 km, it seems reasonable to assume that the
number of creatinine measurements carried out by other labora-
tories must have been negligible. To check this assumption, the only
provider of clinical chemistry services at the national level was
contacted. It was confirmed that the number of analyses of
creatinine performed in patients from Tromsø was very low: fewer
than 100 for the last 5 years of the study period. Accordingly, the
database contained the results of virtually all analyses of creatinine
performed on inhabitants of Tromsø in the study period.
GFR was estimated for all measurements of creatinine in the
database from the Modification of Diet in Renal Disease abbreviated
formula. Only measurements before initiation of first time RRT
were included. The formula estimates GFR from creatinine, gender
and age as 186.3 (serum creatinine)1.154 age0.203 0.742 for
women 1.21 if African American (Levey AS et al. J Am Soc Nephrol
2000; 11: A0828, abstract).21 The database included date of birth
and a person number encoding gender. Age at the time of measure-
ment was used for each estimate. The number of inhabitants of African
descent in Tromsø was negligible, and the last factor was ignored.
Patients having GFR less than 60 ml/min/1.73 m2 for 3 months or
more have CKD according to the National Kidney Foundation
Kidney Disease Outcomes Quality Initiative definition.2 GFR from
30–59 ml/min/1.73 m2 is classified as CKD stage 3. All GFR estimates
in the study period in this interval were identified. When the
identified measurements were followed by a second measurement in
the same interval 90 days or more after the first, the patient was
classified as having CKD stage 3 if there were no measurements
outside the interval between the two. The observation time of each
patient was defined to start 3 months after the date of the first
registered measurement satisfying these criteria. Persons younger
than 20 years were not included.
Measurements
Serum creatinine analyses were performed with instruments from
Roche Diagnostics (GmbH, 68 298 Mannheim, Germany). The
model Hitachi 917 was used from 1994 to 2002 and from 2002 the
Modular model from Hitachi was used. A Jaffe method with
reagents and calibrators purchased from the same company was
used. Control samples with three levels of creatinine were analyzed
for every 100 patient samples. An analytical coefficient of variation
of 2% was used in the internal quality control system. The
occurrence of two consecutive control observations exceeding the
same mean72 s.d. was used as rejection rule. Calibrations were
performed when necessary. The laboratory participated in an
External Quality Assessment Program provided by Labquality,
Helsinki, FI, USA.
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Outcomes
Death and renal failure were considered competing risks. Renal
failure was defined as either initiation of RRT or CKD stage 5, and
the date of the event that occurred first was registered. CKD stage 5
is defined as GFR less than 15 ml/min/1.73 m2 and was ascertained
from the database as the first date of a GFR below this level with no
subsequent values of 15 or greater before RRT, death, or censoring.2
Patients were censored at the end of the study period.
All initiations of RRT for inhabitants of the municipality are
administered by the University Hospital of North Norway, and the
date of initiation was recorded from hospital databases. Initiation of
RRT in patients who had moved from the municipality was assumed
to be negligible, as migration in persons over 40 years of age to
and from the municipality was very low in the period.20 To
check the completeness of the creatinine database, it was matched
with all patients from Tromsø having initiated RRT in the study
period. Only four of 55 patients did not have any creatinine
measurement previous to 3 months before start of RRT. In two of
these, RRT was started within 3 months of the beginning of the
study period.
Date of death was registered from the hospital’s database, which
is regularly updated against the Norwegian Central Population
Register.
Statistical analysis
The association between estimated GFR and the predictor variables
gender, age at inclusion and time was studied with a multilevel
model.22 At the first level, GFR was assumed to follow a linear
regression on time for each patient:
GFRij ¼ GFR0i þ p1itimeij þ eij ð1Þ
where GFRij is the jth GFR estimate for the ith patient, GFR0i is the
true GFR at inclusion for the ith patient, p1i the true rate of change
in GFR for the ith patient, and eij the residual variation. At the
second level, GFR0i and p1i were modelled in linear models with age
at inclusion and gender as independent variables:
GFR0i ¼ GFR00 þ b01agei þ b02genderi þ z0i ð2Þ
p1i ¼ b10 þ b11agei þ b12genderi þ z1i ð3Þ
where GFR00 represents the population true mean GFR at inclusion
for a 60-year-old male, b01 and b02 the population true effects of age
and gender on GFR at inclusion, respectively, b10 the population
true mean change in GFR for a 60-year-old male and b11 and b12 the
population true effects of age and gender on change in GFR,
respectively. z0i and z1i represent residual variation. Age was entered
as age in years minus 60 (to center the intercept at age 60 years) and
gender as a dichotomous variable with 0 coding for male and 1 for
female.
Substituting for GFR0i and p1i in equation (1) and rearranging
terms gives
GFRij ¼ðGFR00 þ b01agei þ b02genderi
þ b10timeij þ b11ageitimeij
þ b12genderitimeijÞ þ ðz0i þ z1itimeij þ eijÞ
In this equation, the first parenthesis includes the fixed and the
second the stochastic effects of the model. PROC MIXED in SAS
(SAS Institute, Cary, NC, USA) was used for estimating parameters
and confidence intervals. The model used all GFR estimates from the
start of observation till death, initiation of RRT, or censoring.
Interactions between age and gender were tested by including
product terms in (2) and (3).
The possibility of bias because this model gives less weight to
patients with few GFR estimates and a rapid decline in GFR has been
a concern in some studies, and models incorporating informative
censoring have been used.23,24 In the present study, a high
proportion of the study subjects died before the end of the study
period. For these patients, Pearson’s correlation coefficient between
observation time and an ordinary least-squares estimate of change
in GFR for each patient was only 0.03, which does not indicate that
this type of bias was a problem. Accordingly, we chose a model
without informative censoring.
For tabular and graphical presentations of the distribution of
change in GFR, estimates of p1i for each patient under the model
conditional on the observed GFR estimates were used. Compared to
using ordinary least-squares estimates of change in GFR for each
individual patient, this method avoids high variability in estimates
for patients with short follow-up.
Survival analysis of the competing risks of death and renal failure
was performed by estimating non-parametric, maximum-likelihood
estimates of the cumulative incidence of each endpoint in the
presence of the other, as suggested by Kalbfleisch and Prentice.25 The
effects on the competing risks of age, gender, and GFR at baseline
were analyzed with Cox proportional-hazards regression of each
endpoint separately, as outlined by the same authors.25 Nonlinear
effects of age and GFR were tested by including quadratic terms in
the models. These analyses were performed with Number Cruncher
Statistical Systems (Kaysville, UT, USA).
Incidence rate ratios for death and renal failure relative to the
general population of Tromsø standardized to the age and gender
distribution of the CKD stage 3 cohort were estimated as described
by Rothman and Greenland.26 Mortality data were obtained from
the website of Statistics Norway.20
Statistical significance was set at P less than 0.05.
This study was approved by the Norwegian Data Inspectorate
and the Regional Ethics Committee of North Norway.
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